Nirsevimab recommended by FDA Advisory Committee to prevent RSV in infants
June 9th 2023In unanimous fashion, the FDA AMDAC voted 21 to 0 that nirsevimab has a favorable benefit risk profile for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants during their first RSV season.
Medicaid-enrolled children not receiving mental health services after firearm injuries
June 8th 2023Investigators state public health strategies should prioritize early detection of mental health needs and equitable access to it, as some Medicaid-enrolled children are not receiving mental health services following a firearm injury.
FDA warns of drug compounding amid shortages of drugs containing semaglutide
June 7th 2023Semaglutide (Wegovy; Novo Nordisk) for obesity in adolescents, along with 2 other approved products containing semaglutide, are currently on the FDA’s drug shortages list, prompting the agency to warn patients and providers about drug compounding.
2 Clarke Drive
Cranbury, NJ 08512